Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group (Q40446162)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group (English)

1 reference

Europe PubMed Central

20 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

Eastern Cooperative Oncology Group

7

object named as

Eastern Cooperative Oncology Group

1 reference

Europe PubMed Central

20 September 2017

6

object named as

George Wilding

1 reference

Europe PubMed Central

20 September 2017

author name string

Robert Dreicer

1

1 reference

Europe PubMed Central

20 September 2017

Shuli Li

2

1 reference

Europe PubMed Central

20 September 2017

Judith Manola

3

1 reference

Europe PubMed Central

20 September 2017

Naomi B Haas

4

1 reference

Europe PubMed Central

20 September 2017

Bruce J Roth

5

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 August 2007

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

110

1 reference

Europe PubMed Central

20 September 2017

759-763

1 reference

Europe PubMed Central

20 September 2017

4

1 reference

Europe PubMed Central

20 September 2017

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced bladder and urothelial cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Epothilones: mechanism of action and biologic activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22839

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22839

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40446162&oldid=1898057837"